H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential

Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes that the company has 3 major value drivers: the platform technology RaniPill, a recent collaboration agreement with Chugai Pharmaceutical for a hemophilia product, and an additional five drug targets, as well as RT-114, which is an oral GLP-1/GLP-2 dual agonist candidate.

H.C. Wainwright expects data readouts on RT-114 to be the biggest driver of near-term value creation for the company’s shares. A day prior, on October 20, Maxim raised the firm’s price target on Rani Therapeutics to $10 from $5 with a Buy rating on the shares after the company announced the licensing deal with Chugai Pharmaceutical and a concurrent private placement to raise $60 million in proceeds.

Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is a clinical-stage biotherapeutics company that focuses on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with an alternative to painful injections in the US.

While we acknowledge the potential of RANI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.